Diagnostics and Personalized Medicine Committee


The BioNJ Diagnostics and Personalized Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, the government and investors in the State of New Jersey.

The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.

Shiv Krishnan, Ph.D., Senior Director, Scouting & Partnering – US of Sanofi R&D; Elias Zerhouni, M.D., President, Global R&D of Sanofi; Kathleen Otto, Vice President, Business Development of BioNJ; G. Steven Burrill, CEO of Burrill & Company; Marc Bonnefoi, DVM, Ph.D., Head of the North America R&D Hub and Vice President of Disposition, Safety and Animal Research Scientific Core Platform of Sanofi; and Edward Abrahams, Ph.D., President of the Personzalized Medicine Coalition at the 2013 BioNJ Dx & PM Innovation Summit on June 6, 2013 at Sanofi.

G. Steven Burrill, CEO of Burrill & Company; Debbie Hart, President and CEO of BioNJ; Shiv Krishnan, Ph.D., Senior Director, Scouting and Partnering – US of Sanofi R&D; and Roomi Nusrat, M.D., CEO of Aesclepius Sciences LLC at the 2013 BioNJ Dx & PM Innovation Summit on June 6, 2013 at Sanofi.

Committee Members

Pascal Yvon, PharmD, MBA, Committee Co-Chair, President, BioSciences Expansion
Andrew Brooks, Ph.D., Chief Operating Office, RUCDR, Infinite Biologics
Ger Brophy, B.Sc., Ph.D., General Manager, GE Healthcare Peter Hoehn, Global Business Leader, Janssen Diagnostics
Jan De Backer, MSc, Ph.D., MBA, Chief Executive Officer, FluidDA, Inc.
Guanghui Hu, President, Admera Health
Courtney Kronenthal, PhD., Director, Communications and Development, Coriell Institute for Medical Research
Nancy Lurker, Chief Executive Officer, PDI, Inc.
Janet McKim, Director of Development, Human Genetics Institute of NJ, RUCDR, Infinite Biologics
Joe Montemarano, MIRTHE Executive Director, Princeton University
Christopher Moxham, Ph.D., Associate Vice President, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Co.
Roomi Nusrat, M.D., Consultant, Aesclepius Sciences, LLC
Lieven Nuyttens, Chief Executive Officer, U.S. Division, FluidDA, Inc.
Panna Sharma, President & CEO, Cancer Genetics, Inc.
Jacqueline Threadgill, Consultant, Senergene Solutions
Peter Tolias, Ph.D., Professor and Director, Center for Healthcare Innovation, Stevens Institute

Members of the BioNJ Diagnostics and Personalized Medicine Committee
join May 2011 Webinar Panelists at BioNJ Headquarters.

Recent Events

June 6, 2013: Second Annual Diagnostics & Personalized Medicine Innovation Summit

Join Us!

To stay informed of BioNJ’s Diagnostic and Personalized Medicine activities and events, please complete the following information.

Name

Email

Company

Position

Address

Phone

Message

Do you believe Personalized Medicine is the future of healthcare?

View Results

Loading ... Loading ...

Video Archive

      

If you are interested in becoming a sponsor of the BioNJ Diagnostics and Personalized Medicine
Committee, please contact Kathleen Otto at KOtto@BioNJ.org or by phone at 609-890-3185.